10.01.2023 BRAIN Biotech AG  DE0005203947

EQS-Adhoc: BRAIN Biotech AG: prioritizing development of therapeutic applications of the Akribion Genomics technology platform (genome-editing)


 

EQS-Ad-hoc: BRAIN Biotech AG / Key word(s): Strategic Company Decision
BRAIN Biotech AG: prioritizing development of therapeutic applications of the Akribion Genomics technology platform (genome-editing)

10-Jan-2023 / 12:10 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


BRAIN Biotech AG: prioritizing development of therapeutic applications of the Akribion Genomics technology platform (genome-editing)

Zwingenberg, Germany
January 10th, 2023

BRAIN Biotech AG (“BRAIN”) announces that at the Supervisory Board meeting held today, the Executive Management Board of the company with the consent of the Supervisory Board decided to prioritize the development of therapeutic applications of the genome editing activities bundled under the brand name Akribion Genomics, this includes potential applications in oncology. The mode of action of the BRAIN nucleases selected for this purpose allows both the targeted enrichment and depletion by selective destruction of cells. This may open up fields of application in the area of therapeutics with considerable market potential. Akribion Genomics is currently establishing a partner network for the further development of this platform technology in therapeutic, diagnostic and industrial fields of application.


Notifying person:

Martina Schuster, Investor Relations

BRAIN Biotech AG
Darmstädter Str. 34-36, 64673 Zwingenberg, Germany
www.brain-biotech.com

Investor Relations Office
Tel.: +49-(0)-6251-9331-0
Fax: +49-(0)-6251-9331-11
E-Mail: [email protected]

 


Information and Explanation of the Issuer to this announcement:

About BRAIN Biotech

BRAIN Biotech AG is a leading European industrial biotechnology specialist with a focus on nutrition, health and the environment. As a technology and solutions provider the company supports the biologization of industries with bio-based products and processes. From contract R&D with industrial partners to advancing own disruptive incubator projects and customized enzyme products, BRAIN’s broad cutting-edge biotech expertise and its agile teams are key to success. - BRAIN Biotech AG, Germany, is the parent company of the international BRAIN Group, distributing specialty B2B products like enzymes or bioactive natural products. The BRAIN Group has its own fermentation or production facilities in Continental Europe, UK and the US, which together with the associated biotechnological solution competency complete the value chain within the group. - As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption and to actively advance common societal goals. BRAIN Biotech´s products and services target at least five of the UN SDGs directly. - Since its IPO in 2016, BRAIN Biotech AG is listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).


10-Jan-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: BRAIN Biotech AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: [email protected]
Internet: www.brain-biotech.com
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1530979

 
End of Announcement EQS News Service

1530979  10-Jan-2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1530979&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 24,11 27,05 38,56 38,23 38,39 45,51 55,34
EBITDA1,2 -7,70 -6,55 -2,50 -3,88 -2,53 -1,31 -0,83
EBITDA-Marge3 -31,94 -24,21 -6,48 -10,15 -6,59 -2,88
EBIT1,4 -9,37 -9,57 -7,20 -8,23 -6,55 -5,65 -5,48
EBIT-Marge5 -38,86 -35,38 -18,67 -21,53 -17,06 -12,42 -9,90
Jahresüberschuss1 -9,40 -8,37 -11,12 -9,02 -4,68 -6,34 -8,11
Netto-Marge6 -38,99 -30,94 -28,84 -23,59 -12,19 -13,93 -14,66
Cashflow1,7 -5,80 -5,42 -3,38 -4,77 -3,10 -1,49 -4,22
Ergebnis je Aktie8 -0,58 -0,45 -0,61 -0,52 -0,25 -0,30 -0,38
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Baker Tilly

INVESTOR-INFORMATIONEN
©boersengefluester.de
BRAIN Biotech
WKN Kurs in € Einschätzung Börsenwert in Mio. €
520394 3,400 Halten 74,28
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
34,00 0,00 0,00 -7,39
KBV KCV KUV EV/EBITDA
3,41 - 1,34 -119,69
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 12.03.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
28.02.2024 28.05.2024 29.08.2024 17.01.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-9,60% -16,09% -7,10% -41,58%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu BRAIN Biotech AG  ISIN: DE0005203947 können Sie bei EQS abrufen


Biotechnologie , 520394 , BNN , XETR:BNN